GLS-5310 Vaccine in Healthy Volunteers for the Prevention of SARS-CoV-2 (COVID-19)

Healthy Clinical Trial

Official title:

Phase I Study of the Safety, Tolerability and Immunogenicity of GLS-5310 DNA Vaccine Against SARS-CoV-2

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05085639
• Other study ID #: CoV2-002
• Status: Not yet recruiting
• Phase: Phase 1
• Start date: November 2021
• Est. completion date: December 2022

Study information

• Verified date: October 2021
• Source: GeneOne Life Science, Inc.
• Contact: Medical Monitor
• Phone: 610-707-5671
• Email: jmaslow[@]genels.us
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Phase I study of the safety, tolerability and immunogenicity of GLS-5310 DNA vaccine against SARS-CoV-2 (COVID-19)

Description:

This Phase I, randomized, placebo-controlled, dose-ranging, single-blind study will assess the safety, tolerability, and immunogenicity of GLS-5310 DNA vaccine administered intradermally (ID) with or without concomitant intranasal (IN) administration of GLS-5310. Vaccine delivered ID will either be performed by Mantoux injection and followed by suction applied to the skin surface using the Gene-Derm device or Mantous injection alone without applied suction. Vaccine delivered IN will be administered using the MAD300 atomizer.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 30
• Est. completion date: December 2022
• Est. primary completion date: April 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion criteria:

1. Age 18 to 65 years of age

2. Able to provide informed consent

3. Able and willing to comply with study procedures

4. For women of childbearing potential, able and willing to use an approved form of pregnancy prevention during the study

5. Negative test result for the presence of SARS-CoV-2 IgM and IgG antibodies, which indicate recent or prior infection

Exclusion criteria:

1. Persons involved in the care of patients with COVID-19 and health care workers considered, in the opinion of the investigator, to be at increased risk of infection from SARS-CoV-2

2. Persons with symptoms in the past 2 weeks consistent with possible acute SARS-CoV-2 infection to include fever, loss of smell or taste

3. Persons diagnosis of type 2 diabetes mellitus

4. Persons with a diagnosis of chronic kidney disease

5. Persons with a diagnosis of chronic obstructive pulmonary disease (COPD)

6. Persons with a diagnosis of heart conditions to include heart failure, coronary artery disease, prior heart attack, cardiomyopathy

7. Obesity (BMI of 30 kg/m2 or greater)

8. Sickle cell disease

9. Current or former smoker

10. Current or planned pregnancy during the study

11. Currently breastfeeding

12. Current or past participation in a coronavirus (MERS-CoV, SARS-CoV-2) vaccine study, or receipt of a SARS-CoV-2 vaccine that has been approved by the FDA, including vaccines that have received Emergency Use Authorization (EUA)

13. Administration of an investigational agent within 90 days of the 1st dose

14. Administration of a vaccine within 2 weeks prior to the 1st dose

15. Administration of immune globulin within 6 months of enrollment

16. Administration of an anti-TNFa inhibitor such as infliximab, adalimumab, etanercept, or anti-CD20 monoclonal antibody rituximab within 6 months from enrollment

17. Current daily treatment of systemic corticosteroids of 20 mg of prednisone or greater; or the equivalent dose of other systemic corticosteroids

18. Treatment within the four weeks prior to enrollment with any drug intended for the prophylaxis or treatment of COVID-19

19. Any prior treatment with an anti-SARS-CoV-2 monoclonal antibody or immune serum

20. Prior treatment with an anti-IL-6 inhibitor, anti-IL-1 inhibitor, anti-TNF monoclonal antibody, or anti-JAK inhibitor (see Appendix B exclusionary period for specific drugs)

21. History of malignancy

22. History of transplantation (any organ or bone marrow)

23. Current or planned chemotherapy treatment for hematologic or solid tumor during study period

24. History of other congenital or acquired immunodeficiency, excluding those with HIV infection who are taking highly active antiretroviral therapy and who have documentation of undetectable serum viral load

25. History of PCR-confirmed infection with SARS-CoV-2

26. Not willing to allow storage and future use of samples for SARS-CoV-2 related research and who have a CD4 count > 200 cells/µL on two measures at least 3 months apart

27. Prisoner or subjects who are compulsorily detained for treatment of a psychiatric illness

28. Any illness or condition that, in the opinion of the investigator, may affect the safety of the subject or the evaluation of a study endpoint

Exclusion criteria (ID + IN only):

29. History of chronic rhinosinusitis

30. History of nasal septal defect or deviated nasal septum

31. History of cleft palate

32. History of nasal polyps

33. History of other disorders that, in the opinion of the investigator, may adversely affect administration of intranasal vaccine

Related Conditions & MeSH terms

• COVID-19
• Covid19
• Healthy

Intervention

Biological:
• GLS-5130
GLS-5310 DNA plasmid vaccine
• Placebo
Placebo

Locations

Country	Name	City	State
Puerto Rico	Clinical Research Puerto Rico	San Juan
Puerto Rico	University of Puerto Rico	San Juan

Sponsors (1)

Lead Sponsor	Collaborator
GeneOne Life Science, Inc.

Country where clinical trial is conducted

Puerto Rico, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Determine IgG antibody responses after a single dose of GLS-5310 related to treatment arm	Endpoint titer of binding antibody in serum at each timepoint	Through 56 weeks post vaccination
Other	Determine IgA antibody responses following vaccination of GLS-5310 related to treatment arm		Through 56 weeks post vaccination
Primary	Incidence of adverse events	solicited/unsolicited local and systemic AEs	Through 56 weeks post vaccination
Primary	Geometric mean titer (GMT) of antigen specific antibody titers	Endpoint titer of binding antibody in serum	Through 56 weeks post vaccination
Secondary	Evaluation of positive response rate of T cell responses induced by GLS-5310	T-cell response of antigen-specific interferon - gamma (IFN-?) secretion in PBMC at each timepoint	Through 56 weeks post vaccination
Secondary	Geometric mean titer (GMT) of neutralizing antibody titers	Plaque-reduction neutralizing titer(PRNT) in serum at each timepoint	Through 56 weeks post vaccination